Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Public ClinicalTrials.gov record NCT01117350. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) \< 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents Secondary objectives of the comparative period (24 weeks): \>To assess the effect of insulin glargine in comparison with liraglutide on: * HbA1c level * Percentage of patients whose HbA1c has decreased but remains \>= 7% at the end of the comparative period * Percentage of patients whose HbA1c has increased at the end of the comparative period * Fasting Plasma Glucose (FPG) * 7-point Plasma Glucose (PG) profiles * Hypoglycemia occurrence * Body weight * Adverse events Objectives of the extension period (24 weeks): \>To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on: * HbA1c level * FPG * 7-point PG profiles * Hypoglycemia occurrence * Body weight * Adverse events
Study identification
- NCT ID
- NCT01117350
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 978 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- Oct 2012 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Apr 11, 2014
2010 – 2013
United States locations
- U.S. sites
- 45
- U.S. states
- 21
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840023 | Birmingham | Alabama | 35294 | — |
| Investigational Site Number 840002 | Goodyear | Arizona | 85395 | — |
| Investigational Site Number 840047 | Phoenix | Arizona | 85020 | — |
| Investigational Site Number 840017 | La Jolla | California | 92037 | — |
| Investigational Site Number 840036 | La Mesa | California | 91942 | — |
| Investigational Site Number 840037 | Loma Linda | California | 92357 | — |
| Investigational Site Number 840045 | Long Beach | California | 90822 | — |
| Investigational Site Number 840048 | Mission Hills | California | 91345 | — |
| Investigational Site Number 840033 | Mission Viejo | California | 92691 | — |
| Investigational Site Number 840019 | Palm Springs | California | 92262 | — |
| Investigational Site Number 840039 | San Diego | California | 92101 | — |
| Investigational Site Number 840042 | San Diego | California | 92161 | — |
| Investigational Site Number 840043 | Tustin | California | 92780 | — |
| Investigational Site Number 840028 | Denver | Colorado | 80220 | — |
| Investigational Site Number 840034 | Grand Junction | Colorado | 81501 | — |
| Investigational Site Number 840026 | Longmont | Colorado | 80501 | — |
| Investigational Site Number 840022 | Lawrenceville | Georgia | — | — |
| Investigational Site Number 840029 | Roswell | Georgia | 30076 | — |
| Investigational Site Number 840009 | Arlington Heights | Illinois | 60004 | — |
| Investigational Site Number 840051 | Springfield | Illinois | 62704 | — |
| Investigational Site Number 840050 | Indianapolis | Indiana | 46222 | — |
| Investigational Site Number 840031 | Kansas City | Kansas | 66160 | — |
| Investigational Site Number 840004 | Paducah | Kentucky | 42003 | — |
| Investigational Site Number 840010 | Rockville | Maryland | 20850 | — |
| Investigational Site Number 840038 | Eagan | Minnesota | 55122 | — |
| Investigational Site Number 840030 | Minneapolis | Minnesota | 55414 | — |
| Investigational Site Number 840012 | St Louis | Missouri | 63128 | — |
| Investigational Site Number 840044 | St Louis | Missouri | 63141 | — |
| Investigational Site Number 840015 | Atco | New Jersey | 08004 | — |
| Investigational Site Number 840008 | Blackwood | New Jersey | 08012 | — |
| Investigational Site Number 840027 | Mineola | New York | 11501 | — |
| Investigational Site Number 840011 | Staten Island | New York | 10301-3914 | — |
| Investigational Site Number 840005 | Hickory | North Carolina | 28601 | — |
| Investigational Site Number 840052 | Winston-Salem | North Carolina | 27103 | — |
| Investigational Site Number 840049 | Fargo | North Dakota | 58103 | — |
| Investigational Site Number 840006 | Bryan | Ohio | 43506 | — |
| Investigational Site Number 840035 | Cincinnati | Ohio | 45220 | — |
| Investigational Site Number 840016 | Carnegie | Pennsylvania | 15106 | — |
| Investigational Site Number 840020 | Uniontown | Pennsylvania | 15401 | — |
| Investigational Site Number 840024 | Rapid City | South Dakota | 57701 | — |
| Investigational Site Number 840001 | Dallas | Texas | 75230 | — |
| Investigational Site Number 840007 | Dallas | Texas | 75246 | — |
| Investigational Site Number 840013 | Houston | Texas | 77030 | — |
| Investigational Site Number 840014 | Renton | Washington | 98057 | — |
| Investigational Site Number 840046 | Spokane | Washington | 99220-3649 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01117350, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01117350 live on ClinicalTrials.gov.